888
Participants
Start Date
April 30, 2010
Primary Completion Date
May 31, 2012
Study Completion Date
May 31, 2012
exenatide
subcutaneous injection, 5mcg or 10mcg, twice a day
basal insulin
subcutaneous injection, dosing according to physician's clinical judgment
Research site, Acquaviva delle Fonti
Research site, Anzio
Research site, Bassano del Grappa
Research site, Bologna
Research site, Brindisi
Research site, Cagliari
Research site, Campi Salentina
Research site, Casarano
Research site, Caserta
Research site, Cesena
Research site, Chieri
Research site, Cisternino
Research site, Copertino
Research site, Cremona
Research site, Distretto Vittoria
Research site, Fermo
Research site, Ferrara
Research site, Fidenza
Research site, Florence
Research site, Forlì
Research site, Genova
Research site, Germaneto
Research site, Lecce
Research site, Livorno
Research site, Lucca
Research site, Manfredonia (Le)
Research site, Mariano Comense
Research site, Messina
Research site, Milan
Research site, Monza
Research site, Napoli
Research site, Novara
Research site, Olbia
Research site, Palermo
Research site, Palmi
Research site, Parma
Research site, Pavia
Research site, Pisa
Research site, Potenza
Research site, Rimini
Research site, Roma
Research site, Rossano Scalo
Research site, Salerno
Research site, San Giovanni Rotondo
Research site, Schio
Research site, Sesto San Giovanni
Research site, Siena
Research site, Treviso
Research site, Trieste
Research site, Varese
Lead Sponsor
Eli Lilly and Company
INDUSTRY
AstraZeneca
INDUSTRY